Figure 1
AES16-2M treatment accelerated wound healing in an in vivo model. Full-thickness wounds were created on the back of BALB/c wild-type (A,B) and BALB/c-nude (C,D) mice. Each group was treated with 50 μl Pluronic® F-127 gel containing either PBS, AES16-2M, control peptide, or EGF. (A) A photographic record of wound healing was processed on days 0, 3, and 8 post-injury. Scale bar: 1 cm. (B) The residual wound area was calculated as the ratio of the relative wound area to the original wound area on day 0 post-injury (n = 5). Error bars, mean ± SD. *p < 0.05, **p < 0.01 (AES16-2M treatment group versus PBS treatment group), two-tailed student t test. (C) A photographic record of wound healing was processed on days 0, 3, and 11 post-injury. Scale bar: 1 cm. (D) The residual wound area was calculated as the ratio of the relative wound area to the original wound area on day 0 post-injury (n = 8). Error bars, mean ± SD. *p < 0.05 (AES16-2M or EGF treatment group versus PBS treatment group), two-tailed student t test.
